幽门螺杆菌靶向核酸疫苗的构建及免疫学评价

图1 重叠延伸PCR扩增靶向片段hIgZ电泳图谱. 1: P1P2融合基因片段; 2: P3P4融合基因片段; 3: P5P6融合基因片段; 4: 靶向片段hIgZ; M: DNA MarkerⅠ.

图2 重组质粒pFShIgZ酶切鉴定图谱. M: DNA MarkerⅢ; 1: pFShIgZ/ BamHⅠ+EcoRⅤ.

图3 重叠延伸PCR扩增katAhIgZ基因片段. 1: pDNAhIgz(+)和pDNAhIgz(-)扩增片段; 2: pDNAkat(+)和pDNAkatlinker(-)扩增片段; 3: 融合基因片段katAhIgZ; M: DNA Marker.

图4 重组质粒pcDNAkatA和pcDNAkatAhIgZ酶切鉴定图谱. 1: pcDNAkatA/KPnI+EcoRⅠ; 2: pcDNAkatAhIgZ/KPnI+EcoRⅠ; M: DNA MarkerⅢ.

图5 rKatA Ni柱纯化SDS-PAGE图谱. M: Protein Marker; 1: rKatA包涵体; 2: 上柱样品; 3: 穿透峰样品; 4: 洗涤峰样品; 5: 洗脱峰样品.

图6 间接免疫荧光分析转染293T细胞. A: pcDNA3.1(-); B: pcDNAkatA; C: pcDNAkatAhIgZ.

图7 转染293T细胞裂解液和IgG抗体亲和力测定.

图8 小鼠抗过氧化氢酶IgG抗体效价测定.

图9 小鼠抗过氧化氢酶IgG抗体分型测定.